drugset / Trial / NCT00841581
Lucentis to Treat Pigment Epithelial Detachment
Phase 2
Completed
32 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Novartis Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Patients with Pigment Epithelial Detachments secondary to Age-Related Macular Degeneration (AMD) will receive intravitreal Lucentis monthly for 6 months in the hope of improving visual acuity from a baseline evaluation.
Timeline
- Start
- 2008-12
- Primary completion
- 2011-09
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |